8-K: Tomi Environmental Solutions Reaffirms 2026 Revenue Guidance

Tomi Environmental Solutions reaffirms its $12 million revenue guidance for 2026, citing strong first-half performance and a $35 million sales pipeline.

Summary

• Tomi Environmental Solutions (TOMZ) reaffirmed its revenue guidance of at least $12 million for fiscal year 2026.
• The company reported over 100% increase in sales and receipts compared to 2025, surpassing the full 2025 sales in the first half of 2026.
• As of July 29, 2026, TOMI has secured $6.2 million in booked orders and has an additional $8.6 million of its $35 million sales pipeline in advanced stages.
• The merger with Carbonium Core is on track for closing in the second half of 2026, with Carbonium conducting a pilot study for nuclear-grade graphite.
• All four key metrics (BIT Solution sales, mobile equipment sales, single applicator sales, and support services) showed year-over-year and sequential growth in Q2 2026.
• The company is expanding into new markets including robotaxis, biosecurity, drones, and humanoid robotics, with significant international growth in Europe.
• TOMI's SteraMist technology has gained approval in multiple European countries and is being deployed in response to an Ebola outbreak in Israel.
• The company is also seeing growth in the defense sector with approvals from contractors in Korea and defense agencies in Canada, and is working with the Defense Logistics Agency.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, with the reaffirmation of guidance, strong sales growth, and progress on a strategic merger indicating solid operational execution and promising future prospects.

Positives

• Reaffirmed revenue guidance of at least $12 million for fiscal year 2026.
• Sales and receipts increased by over 100% in the first half of 2026 compared to the same period in 2025, exceeding full-year 2025 sales.
• Secured $6.2 million in booked orders and has $8.6 million of its $35 million sales pipeline in advanced stages.
• All four key performance metrics (BIT Solution sales, mobile equipment sales, single applicator sales, support services) showed growth in Q2 2026.
• Significant international expansion with SteraMist approvals in multiple European countries and growing partnerships.
• Advancements in the defense sector with approvals from Korean contractors and Canadian agencies, and a partnership with the Defense Logistics Agency.
• The merger with Carbonium Core is progressing, aiming to enter the nuclear materials sector.
• Positive developments in biosafety cabinet decontamination standards, favoring SteraMist's technology.

Negatives

• The filing is a preliminary financial results announcement, with full audited results not yet available.
• While revenue guidance is reaffirmed, the actual achievement of $12 million is still a forward-looking statement.
• The company relies on the successful closing of the Carbonium Core merger for strategic pivot into the nuclear materials sector.

Risks

• The success of the Carbonium Core merger is subject to closing conditions and potential unforeseen issues.
• Reliance on future sales orders and contracts for revenue generation.
• Potential for actual results to differ materially from forward-looking statements due to various risks and uncertainties.
• Competition in disinfection and decontamination solutions.
• Regulatory approvals and market acceptance in new international markets.
• The company's reliance on a single or a few products for a majority of revenues.
• General business and economic conditions could impact sales and operations.
• The effectiveness and market adoption of new growth areas like robotaxis and humanoid robotics.

Future Outlook

The company reaffirms its revenue guidance of at least $12 million for fiscal year 2026, driven by strong first-half performance, a growing sales pipeline, and international expansion. The merger with Carbonium Core is expected to close in the second half of 2026, positioning TOMI for growth in the nuclear materials sector. Continued expansion in defense, biosecurity, and new technology markets is anticipated.

Management Comments

• "We are pleased with the continued momentum across the SteraMist iHP business. With three consecutive quarters of growth, a quality pipeline, meaningful defense sector progress, and an expanding global partner network, TOMI is executing well on multiple fronts. We remain confident in the Company's trajectory and believe we are well positioned for continued progress throughout the remainder of 2026 and beyond."
• "This is an exciting period for our business and shareholders. In addition to the strong performance of TOMI's business, the merger with Carbonium Core marks a strategic pivot into the high-growth nuclear materials sector, driven by demand from AI infrastructure and defense applications."
• "Nuclear graphite is a critical, irreplaceable material for the future of clean energy, serving as a primary moderator, and structural component in next generation reactor design."
• "Demand for high purity nuclear graphite is accelerating rapidly due to the global push for decarbonization and energy security, with the International Energy Agency projecting that annual investment in nuclear projects will need to double to $120 billion by 2030."

Industry Context

StockSavvy.ai notes that TOMI's reaffirmation of revenue guidance and strong pipeline indicate continued execution in the specialized disinfection and decontamination market. The strategic pivot towards nuclear materials via the Carbonium merger aligns with global trends in clean energy and defense, potentially offering significant long-term growth, though it introduces new market dynamics and risks.

Comparison to Industry Standards

• The reported over 100% sales growth in the first half of 2026 significantly outpaces typical growth rates for established companies in the industrial equipment and specialized chemical sectors.
• The $35 million sales pipeline, with $8.6 million in advanced stages, suggests a robust sales funnel, though direct industry benchmarks for pipeline conversion rates are highly specific to business models.
• The company's expansion into European markets with SteraMist approvals reflects a common strategy for global players, but the pace of regulatory approvals and market penetration varies widely.
• The focus on nuclear-grade graphite aligns with emerging trends in advanced materials for next-generation reactors, a niche market with high growth potential but also significant technical and regulatory hurdles, unlike traditional chemical or equipment suppliers.

Stakeholder Impact

• Shareholders: Potential for increased value through reaffirmed revenue guidance, strong sales pipeline, and strategic merger into the nuclear materials sector.
• Employees: Continued growth and expansion may lead to job creation and opportunities within new market segments.
• Customers: Access to advanced disinfection and decontamination solutions, with potential for new applications in emerging technology sectors.
• Suppliers: Increased demand for BIT solution and equipment may benefit raw material and component suppliers.
• Creditors: Improved financial performance and revenue growth could strengthen the company's creditworthiness.

Next Steps

• Closing of the merger with Carbonium Core in the second half of 2026.
• Continued pursuit of new growth markets including robotaxis, biosecurity, drones, and humanoid robotics.
• Anticipating SteraMist approvals in France, Switzerland, Ireland, Poland, Portugal, and Romania.
• Streamlining and accelerating government procurement of SteraMist iHP Technology through a partnership with the Defense Logistics Agency.
• Supporting the close of a pharmaceutical client's order for SteraMist systems.
• Moving to full-scale commercial production of nuclear-grade graphite post-merger.

Key Dates

Recommendation

The company is executing well with reaffirmed guidance and strong pipeline growth, and the strategic merger into nuclear materials is promising. However, the actualization of these plans, particularly the merger's success and the performance in new high-growth sectors, carries inherent risks that warrant a 'hold' recommendation pending further clarity and execution.

Keywords

disinfection solutions, decontamination, SteraMist, iHP technology, biosafety cabinets, nuclear graphite, merger, European expansion